| 7/22/2015 | BKIG | St. Jude Medical eyes new loan, notes to fund Thoratec acquisition
|
| 3/31/2011 | CVLM | Thoratec calls convertibles due 2034; notes convertible until May 16
|
| 1/28/2011 | CV | Market Commentary: GMX gains on partial tender news; Ford preferreds add dollar neutral; Microsoft slips
|
| 7/31/2009 | SS | Thoratec, HeartWare merger terminated following FTC challenge
|
| 7/30/2009 | SS | Thoratec, HeartWare proposed merger stalled by FTC court challenge
|
| 7/30/2009 | SS | Market Commentary: Cablevision goes ahead with spinoff; Microsoft, Yahoo! deal questioned; Thoratec merger halted
|
| 3/26/2009 | SS | Thoratec, HeartWare to respond to FTC's second request
|
| 9/29/2008 | CV | Holders may convert Thoratec's senior subordinated convertibles due 2034
|
| 2/23/2007 | CV | Reaping lessons from Wild Oats: Market value-based make-whole feature caps protection, says Lehman
|
| 10/31/2006 | BT | Thoratec rated sector perform by RBC
|
| 8/1/2006 | BT | Thoratec kept at sector perform by RBC
|
| 7/31/2006 | BT | Thoratec posts $337,000 second quarter net income, says strong VAD sales helped boost revenues
|
| 5/31/2006 | BT | Thoratec completes enrollment in Bridge-to-Transplantation arm of HeartMate trial
|
| 5/16/2006 | BT | Thoratec to add 90 patients in HeartMate trial
|
| 4/13/2006 | BT | Thoratec expects preliminary first-quarter revenues of $48 million
|
| 2/6/2006 | BT | Thoratec adds $20 million to stock repurchase program
|
| 1/12/2006 | BT | Thoratec: Phase 2 trial for HeartMate ventricular assist device enrolls 200 patients
|
| 1/6/2006 | BT | Thoratec to expand with purchase of $14 million property
|
| 11/7/2005 | BT | Thoratec receives commercial approval for HeartMate II in Europe
|
| 6/8/2004 | CV | Thoratec greenshoe exercised, raising convertibles to $143.75 million
|
| 5/19/2004 | CV | New Issue: Thoratec $125 million discount cash-to-zero convert yields 2.375%, up 37.5%
|
| 5/19/2004 | CV | Market Commentary: Calpine up after big drop last week; Kroll bonds flag while stock soars on merger news
|
| 5/18/2004 | CV | Market Commentary: Tower prices wide of revised talk, jumps to 105.5 area; TXU climbs on new plan; Wyeth off on verdict
|
| 5/17/2004 | CV | Thoratec $125 million discount cash-to-zero convert talked at 2.0-2.5%, up 37.5-42.5%
|
| 5/17/2004 | CV | Market Commentary: Protein Design Labs plunges, Millennium set to rise on drug results; Thoratec, Tower deals emerge
|
| 1/23/2002 | CV | Thoratec to redeem 43/4% convertibles
|
